首页> 外文期刊>Emerging Infectious Diseases >Response to Emerging Infection Leading to Outbreak of Linezolid-Resistant Enterococci
【24h】

Response to Emerging Infection Leading to Outbreak of Linezolid-Resistant Enterococci

机译:对新发感染的反应导致耐利奈唑胺的肠球菌暴发

获取原文
           

摘要

Linezolid was approved in 2000 for treatment of gram-positive coccal infections. We performed a case–control study during a hospital outbreak of linezolid-resistant en-terococci (LRE) infections, comparing cases of LRE infec-tion (cases) with linezolid-sensitive enterococci infections (controls). Nasal and perirectal swab samples were ob-tained from all patients in a 1-day point-prevalence survey. We examined antimicrobial drug use and calculated the defi ned daily dose of linezolid per 1,000 patient-days. Fif-teen LRE cases were identifi ed (13 Enterococcus faecalis and 2 E. faecium); 7 were vancomycin-resistant. Compared with controls, case-patients had increased in-hospital mor-tality rates and lengths of stay. Multivariate analysis identi-fi ed independent predictors of LRE infection: prior cultures positive for methicillin-resistant Staphylococcus aureus (ad-justed odds ratio [AOR] 27), hospitalization duration before index culture (AOR 1.1 per day), and duration of preceding linezolid therapy (AOR 1.1 per day). Linezolid exposure and patient-to-patient transmission appear to be responsible for LRE infections, an important emerging hospital problem
机译:利奈唑胺于2000年被批准用于治疗革兰氏阳性球菌感染。我们在医院对利奈唑胺耐药的肠球菌(LRE)感染暴发期间进行了一项病例对照研究,将LRE感染病例(病例)与利奈唑胺敏感性肠球菌感染(对照)进行了比较。在为期1天的患病率调查中,从所有患者中获得鼻和直肠周拭子样本。我们检查了抗菌药物的使用情况,并计算了每千名患者每天定义的利奈唑胺每日剂量。确认了15例LRE病例(13例粪肠球菌和2例粪肠球菌)。 7例对万古霉素耐药。与对照组相比,案例患者的住院死亡率和住院时间都有所增加。多变量分析确定了LRE感染的独立预测因子:耐甲氧西林金黄色葡萄球菌的先前培养阳性(调整比值比[AOR] 27),指数培养之前的住院时间(每天AOR 1.1)和先前利奈唑胺的持续时间治疗(每天AOR 1.1)。利奈唑胺暴露和患者之间的传播似乎是导致LRE感染的原因,LRE感染是一个重要的新兴医院问题

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号